Learning objectives
To identify non-malignant conditions that affect the prostate.
To recognize prostate zonal anatomy and age-related changes.
To discuss MRI findings of benign prostatic diseases.
Background
There has been a substantial spread of multiparametric magnetic resonance imaging(mpMRI) for prostate cancer management (PCa). Consequently, prostatic benign conditions become more encountered, including benign prostatic hyperplasia (BPH), prostatitis, benign tumors, and congenital anomalies.
The prostate is divided into four glandular zones: peripheral zone (PZ), central zone (CZ), transition zone (TZ), periurethral glands (PUGs), and one stromal zone, the anterior fibromuscular stroma (AFMS) (Fig. 1). T2-weighted MRI (T2WI) provides the best tissue contrast to delineate zonal anatomy.
1.Benign prostatic hyperplasia
It's a histologic diagnosis, referring...
Findings and procedure details
1.Benign prostatic hyperplasia
1.1.Pathophysiology and imaging correlation
Involves the TZ and PUGs (Fig. 2), comprising both glandular (T2WI high signal) and stromal (T2WI low signal) enlargements [5] (Fig. 3).
Two mechanisms proposed to LUTS, but most commonly both coexist:
Static effect: increased bulk from epithelial hyperplasia causing bladder outlet obstruction (BOO);
Dynamic effect: stromal hyperplasia resulting in increased muscle tone around the urethra [6].
Moreover, the distortion of urethra causes more obstruction than compression. Therefore, the hyperplasia site rather than size may be the dominant...
Conclusion
Several symptomatic and asymptomatic benign conditions may clinically simulate PCa in the course of general screening, or may pose as incidental findings on pelvic studies. In this context, benign conditions should be well recognized and accordingly included in the differential diagnoses.
Personal information and conflict of interest
E. Pacheco; São Paulo/BR - nothing to disclose C. T. S. Guimaraes; SAN FRANCISCO, CA/BR - nothing to disclose L. Bittencourt; Rio de Janeiro/BR - nothing to disclose R. F. T. Romano; São Paulo/BR - nothing to disclose L. Sauer; São Paulo/BR - nothing to disclose M. P. Ferri; São Paulo/BR - nothing to disclose
References
Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. 2018;200(3):612-619.
Krieger JN,Lee SW,Jeon J,et al. Epidemiology of prostatitis.Int J Antimicrob Agents.2008;31Suppl1:S85-90.
Curran S, Akin O, Agildere AM, et al. Endorectal MRI of Prostatic and Periprostatic Cystic Lesions and Their Mimics; AJR 2007;188:1373–79.
Game X, Berlizot P, Hassa T, et al. Congenital Pelvic Arteriovenous Malformation in Male Patients. European Urology 2002;42(4):407-412
Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):152-157.
Wasserman NF,...